Key Takeaways
- Domestic volume engine fires, exports sputter: Domestic Crop Care grew 11% on 17% volume growth, while exports remain challenged by China-led pricing pressure and weak demand recovery.
- Seeds turnaround gains traction: Revenue surged 48% as calibrated placement via the Seedsay tool slashed sales returns; the Diggaz cotton brand crossed ₹50 crore with negligible returns.
- Acephate is the unresolved drag: The product faces structural disadvantages against backward-integrated competitors in Brazil and the US; management is evaluating all options, including a possible exit, but has no timeline.
- Margins under near-term pressure: Management flagged short-term margin compression from pricing headwinds and investment needs, even as long-term prospects remain intact.
- What to watch next quarter: Rabi demand uptake on healthy reservoir levels, progress on the domestic portfolio rationalization exercise, and any clarity on the Acephate resolution path.
Domestic Crop Care: Volume-Led Growth
- Volume outperformance: The 17% volume growth was led by herbicide (25%) and crop nutrition (29%), categories where Rallis is consciously working to improve its under-indexed share.
- Monsoon disruption: Erratic rainfall with extensive spells during the key August-September spray window suppressed pesticide applications, particularly hurting herbicide category volumes.
- New launches gaining ground: Clasto (Cotton Whitefly) and Mark Plus (Soyabean Herbicide) showed good promise; Nayazinc and Aquafert (water-soluble fertilizer) are scaling up fast.
- Channel inventory in check: Management believes there is no excess inventory in the domestic crop care channel that would cause problems, as the Kharif season extends into October for pulses, late rice, and cotton.
- Portfolio rationalization underway: An exercise to streamline the domestic formulation portfolio should complete in a couple of months; from FY26, Rallis will evaluate whether each sale is desirable, though the impact on the bottom line is not expected to be meaningful.
Dr. Gyanendra Shukla: "I am going to focus on domestic branded business where I have to make sure my product is being used more by the same farmer and on the more crop acres. That's where our focus is because prices are variable."
Seeds: The Returns-Reduction Story
- The Seedsay effect: Revenue growth of 48% was driven primarily by lower Kharif sales returns, achieved through calibrated placement using the Seedsay digital tool, rather than by volume expansion.
- Volume and price mix: Growth came largely from price and mix (high single-digit), while volume was flattish due to inventory constraints; cotton became the largest crop in the portfolio.
- Diggaz scales, Aatish fades: The cotton hybrid Diggaz crossed ₹50 crore in brand revenue with negligible returns, while the mature product Aatish is on a declining trajectory.
- Margin improvement despite cotton mix: Even though cotton typically carries the lowest margin profile in seeds, operating margin improved due to product mix within the cotton portfolio, revenue growth, operating leverage, and overhead optimization.
- Profitability-first approach: Management wants to manage seeds for profitability and "fit to run," aiming to reach a fitness level where the business does not make losses at all; the goal is to move into the positive zone and then keep improving.
- Market share ambition: Rallis aims to reach at least high single-digit or low double-digit market share in the ₹10,000 crore addressable seed segment, up from the current ~4%, with near-term gains expected from cotton and rice.
Dr. Gyanendra Shukla: "Our aim would be that, look, we come to respectable at least a high single digit or low double digit. It all depends on the portfolio, because every seed business is a product business, there is nothing called me too here, your product must perform, otherwise even if you give it free to the farmer he won't buy it."
Exports: Pricing Pressure and Structural Challenges
- Demand recovery elusive: Export demand recovery is not promising; lower prices and volatility are causing inventory buildup, with China keeping the market well supplied.
- Bright spots in the portfolio: Metribuzin achieved its highest ever H1 volume, already surpassing full FY24 volume; Hexaconazole has good momentum with debottlenecking underway; Pendimethalin has steady long-term demand with capacity expansion using new efficient technologies to be commercialized by end of FY25.
- Acephate remains the trouble child: The market continues under pressure in the US and Brazil, with key input raw material at its lowest ever price; Rallis is disadvantaged against competitors Adama and UPL, who are significantly backward-integrated and have B2C presence in those concentrated markets.
- Resolution options under review: Management is evaluating cost reengineering on manufacturing and developing B2C presence or supplier relationships in key markets; the easier option would be to exit the product, but the company is not at that stage yet and wants clarity sooner rather than later, though global dynamics make this slow.
- Measured capacity approach: Rallis will not set up export capacities until it has contracts in hand and improved utilization for already set-up capacities.
Dr. Gyanendra Shukla: "The easier option is that if we are not making, we get out of the product, right. I think we are not at that stage yet. Whatever we do, we have to make sure we have all the information, and we have considered all the options."
Contract Manufacturing: Early-Stage Building
- Pilot milestone achieved: Rallis successfully completed pilot-scale production of pre-commercial quantities of Flavocide for Bio-Gene Technology Limited (Australia); the revenue model starts with a supply contract and margin on production, with a future possibility of distribution rights.
- Pipeline in development: Three new contracts were signed in FY24, and management reports multiple conversations at different stages with encouraging responses; the company is a relatively late entrant and is not chasing every opportunity, as big deals are not available at this point.
- Multi-purpose plant utilization: The plant has been used for multiple products including contract manufacturing customers and Difenoconazole (a fungicide launched last year); more products are in the pipeline from international business and contract manufacturing, though higher capacity utilization remains challenging due to the global situation.
Financial Health & Capital Allocation
- Trade receivables increase: Receivables rose ₹80 crore to ₹852 crore, partly from higher domestic sales and partly from the absence of export receivable discounting that was present in the base period; management sees no pocket of concern.
- Higher tax rate: A one-time impact from unwinding of deferred tax assets, triggered by the Union Budget's reduction in long-term capital gains tax, inflated the Q2 tax charge.
- CAPEX plan: The company envisages spends of approximately ₹100 crore, with investment directed toward digital initiatives in both front-end and back-end, plus the Pendimethalin capacity expansion.
- Inventory moderation: Inventory levels have moderated, and collections have improved despite stress in some markets.
Market Context & Outlook
- Global pricing remains subdued: Destocking is largely done, so current-year numbers should look better, but demand is not buoyant; China continues to supply at very competitive rates, and commodity prices are relatively softer for key crops (maize, soybean, cotton) due to good US production estimates and better rainfall in Latin America.
- Rabi outlook positive: Healthy reservoir levels support a positive Rabi season outlook for the domestic business.
- Short-term margin pressure acknowledged: Management stated explicitly that short-term margins will be under pressure, while long-term prospects continue to remain good.
Dr. Gyanendra Shukla: "I am not expecting any miracle to happen in this market. I think it's going to be a normal growth period. Prices will continue to remain subdued given the commodity prices and supply situation."
Dr. Gyanendra Shukla: "While the short-term margin would be under pressure, long-term prospects continue to remain good."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pendimethalin capacity expansion | New efficient technologies to be commercialized | By end of FY25 |
| Domestic formulation portfolio rationalization | Streamlined portfolio approach, evaluating desirability of each sale | Exercise completes in a couple of months; effective from FY26 |
| Seeds profitability | Move to positive zone, then keep improving; seeds should not be a drag on company profitability | No date; "slowly inching towards that" |
| Seeds market share | Reach high single-digit or low double-digit share in ₹10,000 crore addressable segment (from ~4%) | No date; near-term gains from cotton and rice |
| CAPEX | Approximately ₹100 crore | FY25 |
| Export capacity | No new capacities until contracts in hand and improved utilization of existing capacities | Ongoing policy |
| Acephate resolution | Evaluating all options including cost reengineering, B2C presence, or exit; wants clarity sooner rather than later | No fixed timeline; "it takes time" due to global dynamics |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹928 cr, vs ₹832 cr in Q2 FY24 |
| EBITDA | ₹166 cr, 24% higher than Q2 FY24 (₹133 cr) |
| Profit after tax | ₹98 cr, 210% higher than Q2 FY24 (₹82 cr) |
| Domestic crop care revenue growth | 11%, with 17% volume growth |
| Domestic crop care volume growth | 17% |
| Domestic crop care price degrowth (H1 FY25, formulation) | -6% |
| Seeds revenue | ₹141 cr, 48% growth YoY |
| Seeds H1 FY25 volume growth | largely flattish; high single-digit growth from price and mix |
| Export revenue | ₹143 cr |
| Herbicide category growth | 25% |
| Crop nutrition growth | 29% |
| Metribuzin H1 FY25 volume | highest ever, surpassing full FY24 volume |
| Diggaz cotton brand revenue | crossed ₹50 cr |
| Cotton portfolio revenue (FY25 to date) | touched ₹100 cr |
| Cash and liquid balance | ₹229 cr as of 30th September |
| CAPEX envisaged for the year | ~₹100 cr |
| Trade receivables | ₹852 cr, up from ₹773 cr YoY |